The state could introduce a robust platform sometime this week
While it has been a long time coming, Georgia’s medical marijuana program appears to be just around the corner. There are still some unresolved lawsuits from companies that lost out in the licensing bidding process, but the state does not want to waste any more time on the process. The Georgia Medical Cannabis Access Commission is expected to vote on rules governing all aspects of the program in the middle of this week.
The medical cannabis program is getting closer and closer to the state and that is why the commission in charge will soon have to assess the alignments for proper control. From the manufacture of low-THC cannabis oil to treat patients suffering from a variety of illnesses to the cultivation of leaves in greenhouses under close supervision and the sale of the product in a network of dispensaries across the state, these rules will have to be analyzed next Wednesday.
“We’ll have a lot of momentum,” said Andrew Turnage, executive director of the commission. About four months ago, this commission had to vote to grant the first two of six production licenses authorized in a bill passed by the General Assembly in 2019. After endorsing the proposals during a public hearing on August 18, Botanical Sciences and Trulieve Georgia said they were more than ready to get started. Adel will have a Trulieve production facility, while Botanical Sciences will set up a shop in Glennville.
“No time should be wasted approving these rules,” Trulieve president Lisa Pinkney told the commission. “We hope to make a difference for patients in this state.”